---
title: "NewcelX agrees terms to sell Mazindol for $30,000 cash and stock in a company not yet formed"
url: "https://aibio.space/news/newcelx-agrees-terms-sell-mazindol-30-000-cash-stock-company-not-yet/"
event_date: "2026-11-04"
date_published: "2026-11-05"
description: "The $500,000 upfront value is mostly a 9.4% stake in REA Holdings, a buyer led by the former chairman of NewcelX's predecessor. Up to $55 million in milestones and 2% to 8% royalties depend on future development."
---

# NewcelX agrees terms to sell Mazindol for $30,000 cash and stock in a company not yet formed

NewcelX Ltd. (Nasdaq: NCEL) said on November 4, 2026, that it has signed a binding term sheet to sell its worldwide Mazindol portfolio, the legacy assets behind its contingent value rights, to REA Holdings Inc. Of the $500,000 in upfront value the company attributes to the deal, $30,000 is cash. The rest is shares equal to 9.4% of REA's fully diluted equity after closing. REA is a Delaware corporation still under formation, and its promoter, Ronald Hafner, is the former Chairman of NewcelX's predecessor, NLS Pharmaceutics. Chief Executive Officer and Chairman Ronen Twito picked that buyer for a company that reports substantial doubt about its ability to continue as a going concern, and the release gives CVR holders no figure for what they may receive. [Press release](https://www.sec.gov/Archives/edgar/data/1783036/000121390026115753/ea031065001ex99-1.htm)

## The terms

The term sheet provides for $500,000 in attributed upfront consideration: $30,000 in cash and the remainder in REA shares. NewcelX would also be eligible for up to $55 million in development, regulatory and commercial milestone payments, plus tiered royalties of 2% to 8% on annual global net sales of Mazindol products. The release gives no milestone schedule and no royalty thresholds, and it does not explain how it values the REA stake at about $470,000 (the $500,000 less the cash). [Press release](https://www.sec.gov/Archives/edgar/data/1783036/000121390026115753/ea031065001ex99-1.htm)

The milestones and royalties pay only if Mazindol is developed, approved and sold. The $55 million is a ceiling, not an expected amount. Amounts owed to CVR holders will be set under the CVR agreement and applicable law, net of costs NewcelX is entitled to deduct, and the release does not say what those costs are. The deal still needs definitive documents, customary closing conditions and applicable corporate and CVR requirements, and the parties say they will now prepare and negotiate those documents. The release names no financial advisor, no counsel and no fairness opinion. [Press release](https://www.sec.gov/Archives/edgar/data/1783036/000121390026115753/ea031065001ex99-1.htm)

## The buyer

Hafner is proposed as REA's Chairman and Chief Executive Officer. The release says REA is being established by biotechnology-focused business professionals with substantial industry experience and financial capabilities, and by experienced biotech executives led by Hafner with expertise in the CNS space. It names no other founder or investor and gives no figure for REA's capital. Its proposed leadership plans what the release calls a capital-efficient model built on intellectual property, historical clinical data and strategic partnerships. Hafner said REA aims to advance Mazindol through a focused development and partnering strategy. [Press release](https://www.sec.gov/Archives/edgar/data/1783036/000121390026115753/ea031065001ex99-1.htm)

Twito said NewcelX invested significant effort in finding the right buyer and that REA's team is well positioned to drive the opportunity forward. The release says REA was chosen after an extensive search but gives no detail on other bidders. In our reading, a sale to a company that does not yet exist, led by a former chairman of the predecessor, with no stated funding and no independent valuation disclosed, asks CVR holders and shareholders to take the price largely on trust. [Press release](https://www.sec.gov/Archives/edgar/data/1783036/000121390026115753/ea031065001ex99-1.htm)

The portfolio includes transferable intellectual property, clinical and regulatory data, formulations, manufacturing documentation and know-how. After completion, REA would take on patent maintenance, development, regulatory, financing and commercialization costs arising from its operations, subject to the definitive documents. [Press release](https://www.sec.gov/Archives/edgar/data/1783036/000121390026115753/ea031065001ex99-1.htm)

## NewcelX's own cash

The benefit for NewcelX is that it stops paying for Mazindol. Twito said the structure is expected to let Mazindol advance without NewcelX funding its development. The company needs the relief. Its interim financial statements show cash and cash equivalents of $710 thousand at June 30, 2026, down from $2,201 thousand at December 31, 2025. Operating activities used $2,872 thousand in the first six months of 2026, and the net loss was $2,900 thousand. The statements say these conditions raise substantial doubt about the company's ability to continue as a going concern. [Interim financial statements](https://www.sec.gov/Archives/edgar/data/1783036/000121390026101419/ea030514101ex99-1.htm)

In July 2026 the company entered into securities purchase agreements for about $1.4 million in gross proceeds from a private placement, and it reports access to an equity line of credit with a maximum commitment of up to $25.0 million, subject to its terms. Management says existing cash and available financing may not be sufficient to fund operations and capital requirements for at least the next twelve months, and it lists divestitures among the options it is weighing. Set against a half-year operating cash outflow of $2,872 thousand, the $30,000 cash payment is small. [Management's discussion and analysis](https://www.sec.gov/Archives/edgar/data/1783036/000121390026101419/ea030514101ex99-2.htm)

NewcelX describes itself as a regenerative medicine company developing stem-cell-derived therapies for Type 1 Diabetes. Its lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. The release gives no clinical data or timetable for NCEL-101. [Press release](https://www.sec.gov/Archives/edgar/data/1783036/000121390026115753/ea031065001ex99-1.htm)

The filing to watch is the definitive agreement. It should show how many REA shares NewcelX receives, who funds REA and how the CVR holders' share is calculated. [Press release](https://www.sec.gov/Archives/edgar/data/1783036/000121390026115753/ea031065001ex99-1.htm)

Sources

- https://www.sec.gov/Archives/edgar/data/1783036/000121390026115753/ea031065001ex99-1.htm
- https://www.sec.gov/Archives/edgar/data/1783036/000121390026101419/ea030514101ex99-1.htm
- https://www.sec.gov/Archives/edgar/data/1783036/000121390026101419/ea030514101ex99-2.htm
